Igenica raises $5M; AgeneBio bags grant for PhIII-ready Alzheimer's program;

@FierceBiotech: Pfizer's hunting for safe M&A bets, not high-risk pipeline deals. Article | Follow @FierceBiotech

@JohnCFierce: $GSK and $NVS get EU clearance for the Big Swap -- selling some assets along the way. More | Follow @JohnCFierce

@DamianFierce: News to me: $AMGN's PCSK9 blocker will sell as Repatha, which sounds a bit like a mid-sized sports utility vehicle. | Follow @DamianFierce

> Igenica has raised $5 million of a $6.2 million offering, according to a recent SEC filing. The biotech raised $14 million from its venture backers--including Third Rock--about a year ago to move its lead cancer antibody into the clinic. Filing

> AgeneBio picked up a $900,000 grant from the Alzheimer's Drug Discovery Foundation to back its work on AGB101, which it describes as a Phase III-ready low dose formulation of an epilepsy drug. Release

> The OTC biotech Vaccinogen says it's closed a previously reported deal for $10 million to study its therapeutic cancer vaccine OncoVax. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: AdvaMed: China's push for hospitals to buy domestic devices all talk, no action. Article | Follow @FierceMedDev

@EmilyWFierce: Find out which med tech companies scored key device approvals in 2014 in @FierceMedDev's latest special report. Feature | Follow @EmilyWFierce

> St. Jude gains FlexAbility approval, lays out 2015 sales growth strategy. Article

> Illumina soars 32% in Q4 with sales of next-gen sequencing system. News

Pharma News

@FiercePharma: #Pfizer extricates itself from investor lawsuit with $400M payment. More | Follow @FiercePharma

@EricPFierce: Pfizer settles investor suit over marketing probe of Bexta for $400M. Story | Follow @EricPFierce

> Novartis braces for psoriasis pricing war as it preps for Cosentyx launch. Item

> Mylan said to be eyeing a $7B-plus bid for rising star Hikma. More

Drug Delivery News

> PARI snags FDA approval for cystic fibrosis nebulizer platform. News

> Microneedle patch maker Zosano Pharma raises $50M in IPO. Article

> Nanomed lifetime is an important aspect of delivery potential, scientists say. More

> Shire's intrathecally delivered candidate for Hunter syndrome gets FDA's Fast Track Designation. Report

> Australian team developing novel formulation to deliver common diabetes drug. Article

Diagnostics News

> Myriad settles patent feud with Invitae, Pathway Genomics over BRCA technology. News

> Roche nabs FDA OK for drug-resistant bacteria test. More

> Sequenom strikes a deal with Cypher Genomics to develop advanced noninvasive prenatal test. Report

> Sera Prognostics taps industry niche with preterm birth risk test. Story

> Roche's Ventana inches closer to FDA approval for lung cancer companion Dx. Article

Pharma Marketing News

> Novartis revs up Cosentyx launch as it braces for a psoriasis pricing war. News

> Express Scripts takes a bow for cutting $4B off hep C drug spending. Article

> Auryxia differentiation strategy, check. Next, Keryx has to persuade prescribers. Story

> Bayer, J&J launch new stroke study to pump up payer-persuading Xarelto data. More

> Valeant bets big on the Super Bowl with $4.5M toe-fungus ad. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.